NEW YORK--(BUSINESS WIRE)--

The Rosen Law Firm, P.A., a global investor rights law firm, announces that it is investigating the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Hyperion Therapeutics to maximize shareholder value before agreeing to be acquired by Horizon Pharma plc (NASDAQ: HZNP).

If you would like to join the action, go to http://rosenlegal.com/cases-563.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at [email protected] or [email protected]. There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders will receive $46 in cash for each share of Hyperion common stock they own. The proposed transaction is valued at approximately $1.1 billion. The investigation relates to whether the proposal is fair to the public shareholders of Hyperion and whether Hyperion's Board breached its fiduciary duties in connection with the proposed sale.

If you currently own shares of Hyperion and wish to obtain additional information, please visit the website at http://rosenlegal.com/cases-563.html. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.